Patients & Caregivers
Aradigm To Meet with FDA for Linhaliq Review in Early 2018
Aradigm Corporation’s meeting with the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is slated for January 11, 2018.
New Guidelines for Diagnosing LAM Published Today
Additional clinical practice guidelines were published as it pertains to to diagnosing lymphangioleiomyomatosis and the management of pneumothoraces in patients with it.
Vertex Awarding Young Researchers $750,000 To Focus on Cystic Fibrosis
$750,000 research grant program for clinical scientists to establish CF research programs
Haegarda Reduces HAE Attacks by 98% in Most Severe Cases
At the ACAAI Meeting, Dr
Timothy Craig presented data showing the prophylactic use of Haegarda reduced attacks by 98% in severe HAE patients
96-week Study Shows Ofev Continues to be Effective in Slowing IPF Progression
Today, Boehringer Ingelheim previewed the data to be presented at the 2017 CHEST Annual Meeting in Toronto, Canada next week.
New Designation Accelerates Development of Antifungal Drug
Pulmatrix's Pulmazole (PUR1900), designed to fight pulmonary fungal infections, has been designated as a Qualified Infectious Disease Product by the FDA.
PBS Documentary Gene Doctors Explores Rare Diseases
The Gene Doctors
is available. Film explores the scientific breakthroughs that are transforming rare disease patients
Total Hospital Costs for Cystic Fibrosis Patients in U.S. Cost $1.1 Billion per Year
As CF patients are living longer, their hospital costs are also increasing. Costs were $500 million in 2003 vs $1.19 billion in 2013.
FDA Accepts New Drug Application for Treatment of Rare Lung Condition
Aradigm announced the FDA acceptance of its NDA for Linhaliq to treat patients with non-cystic fibrosis bronchiectasis with chronic infections from P. aeruginosa.
Summary of the Clinical Data Of Subcutaneous C1-Inhibitor For Prophylaxis of Hereditary Angioedema
Administration of CSL830 twice weekly at doses 40 IU per kilogram or 60 IU per kilogram has a significant preventive effect
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.